Letrozole
- Generic Name
- Letrozole
- Brand Names
- Femara, Kisqali Femara Co-pack
- Drug Type
- Small Molecule
- Chemical Formula
- C17H11N5
- CAS Number
- 112809-51-5
- Unique Ingredient Identifier
- 7LKK855W8I
- Background
Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.
Letrozole was granted FDA approval on 25 July 1997.
- Indication
Letrozole is indicated to treat postmenopausal women with hormone receptor (HR) positive early breast cancer, postmenopausal women with early breast cancer who have periviously been treated with tamoxifen, and postmenopausal women with HR+ or unknown advanced breast cancer. Letrozole, given with ribociclib, is indicated to treat pre, peri, and postmenopausal women with HR+ and human epidermal growth factor 2 (HER2) negative advanced or metastatic breast cancer.
- Associated Conditions
- Advanced Breast Cancer, Anovulatory cycle, Epithelial Ovarian Cancer, HR+, HER2-, Advanced Breast Cancer, Stage I Breast Cancer, Metastatic HR + HER2 - breast cancer
- Associated Therapies
- -
Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer
- First Posted Date
- 2011-06-07
- Last Posted Date
- 2015-04-03
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 8
- Registration Number
- NCT01368263
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Bioequivalency Study of Letrozole 2.5 mg Tablets Under Fed Conditions
- First Posted Date
- 2011-06-07
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 28
- Registration Number
- NCT01367626
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
Bioequivalency Study of Letrozole 2.5 mg Tablets Under Fasted Conditions
- First Posted Date
- 2011-06-07
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 28
- Registration Number
- NCT01367652
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
Letrozole for Lymphangioleiomyomatosis
- First Posted Date
- 2011-05-12
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 17
- Registration Number
- NCT01353209
- Locations
- 🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
🇺🇸Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸Stanford University Medical Center, Stanford, California, United States
Dosage Optimization for Letrozole Treatment
- Conditions
- First Posted Date
- 2011-03-16
- Last Posted Date
- 2011-03-28
- Lead Sponsor
- Bushehr University of Medical Science
- Target Recruit Count
- 44
- Registration Number
- NCT01315912
- Locations
- 🇮🇷
Bushehr university of medical science, Bushehr, Iran, Islamic Republic of
A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-02-15
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 674
- Registration Number
- NCT01296555
- Locations
- 🇺🇸
Univ of Chicago, Chicago, Illinois, United States
🇺🇸Mary Crowley Cancer Rsch Ctr, Dallas, Texas, United States
🇺🇸Baylor Sammons Cancer Center, Dallas, Texas, United States
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-01-07
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 5018
- Registration Number
- NCT01272037
- Locations
- 🇺🇸
Mills-Peninsula Medical Center, Burlingame, California, United States
🇺🇸Dublin Hematology Oncology Care PC, Dublin, Georgia, United States
🇺🇸Piedmont Fayette Hospital, Fayetteville, Georgia, United States
PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-11-25
- Last Posted Date
- 2016-07-25
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 72
- Registration Number
- NCT01248494
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Massachusetts General Hospital, Dana Farber Cancer Center, Boston, Massachusetts, United States
🇺🇸University of Alabama, Birmingham, Alabama, United States
Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-11-01
- Last Posted Date
- 2021-03-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 72
- Registration Number
- NCT01231659
- Locations
- 🇮🇱
Novartis Investigative Site, Tel Aviv, Israel
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
- First Posted Date
- 2010-10-20
- Last Posted Date
- 2020-08-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 77
- Registration Number
- NCT01225172
- Locations
- 🇺🇸
Oncology Care Associates, P.A., Wheaton, Maryland, United States
🇺🇸Presbyterian Hospital Cancer Research, Charlotte, North Carolina, United States
🇺🇸University Of Virginia Health System, Charlottesville, Virginia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.